vitrivis All writing
Industry

India's Real Breakthrough in Healthcare Is Not the Discovery. It Is the Price.

7 min read

Ask what a medical breakthrough looks like and most people picture a laboratory. A molecule nobody had made before. A paper in a high-impact journal. A press conference.

India has produced some of those. But they are not the most consequential thing happening in Indian healthcare, and treating them as the headline misses what the country has actually got good at.

The breakthrough is manufacturing and delivery. It is taking a therapy or a device that already exists at a price nobody in a middle-income country can pay, rebuilding it locally, and getting the cost down by an order of magnitude without giving up the science. That is a harder problem than it sounds, it is less glamorous than discovery, and India is currently better at it than almost anyone.

The clearest example is a living drug

CAR-T cell therapy re-engineers a patient’s own T-cells to recognise and attack their cancer. It is among the most sophisticated treatments in modern oncology, and until recently it was effectively unavailable in India, because a course cost around $400,000 in the United States.

NexCAR19 changed that. Developed by ImmunoACT, a spin-off from IIT Bombay, in collaboration with Tata Memorial Centre and with support from the Department of Biotechnology and BIRAC, it became India’s first indigenous CD19-directed CAR-T therapy when CDSCO approved it in 2023. It costs roughly $50,000. About one-tenth.

The results were not a compromise for the price. Trial data presented at the American Society of Hematology meeting in December 2023 reported an objective response in 67% of patients — 36 of 53 across two trials — with the cancer disappearing entirely in around half.

The safety profile is the part clinicians tend to find most interesting. The US-approved products use mouse-derived antibody fragments. NexCAR19 is humanised, and the reported toxicity was lower: severe cytokine release syndrome in roughly 5% of patients, and no reported neurologic complications. That matters practically as well as clinically, because CAR-T toxicity requires intensive hospital management, and every complication avoided is cost removed from a system that cannot absorb it.

The US National Cancer Institute wrote about it. That is worth noting, because the usual direction of travel for advanced therapy coverage is not from Washington toward Mumbai.

The context makes the case sharper. New cancer diagnoses in India reached roughly 1.6 million in 2023, up from around 980,000 in 2010, with about 800,000 deaths a year. A therapy priced for American insurance is not a therapy for that population. A therapy priced at one-tenth might be.

The same pattern, repeated across categories

NexCAR19 is not an isolated success. It is the most striking instance of something the National Biopharma Mission has been doing deliberately since 2017.

That mission, co-funded by the World Bank and run through BIRAC, has supported over 100 projects across more than 150 organisations. Among the outputs: India’s first indigenously developed MRI scanner, built at a fraction of the cost of imported machines; the country’s first biosimilar of liraglutide for type 2 diabetes, at close to a third of the imported price; and ZyCoV-D from Zydus Cadila, the world’s first DNA-based COVID-19 vaccine.

Note the shape of that list. One device, one biologic, one genuinely novel vaccine platform. Two of the three are cost breakthroughs on established science. The third is a first in class. That ratio is the honest picture of Indian biomedical innovation right now, and it is not a criticism — the two cost breakthroughs will almost certainly treat more people than the novel platform will.

The underlying industrial base is what makes it possible. India runs the world’s third-largest pharmaceutical sector by volume, supplies around 20% of global generic medicines, exports to roughly 200 countries, and provides more than 70% of the world’s antiretrovirals and 55 to 60% of UNICEF’s vaccines. The bioeconomy has gone from about $10 billion in 2014 to over $165 billion in 2024, with a $300 billion target for 2030.

The Union Budget 2026–27 added Biopharma SHAKTI to this, aimed at biologics and biosimilars manufacturing, a national network of over 1,000 accredited clinical trial sites, three new NIPERs with seven more upgraded, and expanded regulatory capacity at CDSCO. The trial-site network is the quiet detail there. India’s constraint on advanced therapeutics has rarely been ideas or manufacturing. It has been the infrastructure to generate the clinical evidence.

Elimination is a delivery problem, and India solved one

In October 2024, WHO declared that India had eliminated trachoma as a public health problem, with the certificate formally awarded at the 78th World Health Assembly in Geneva in May 2025. India became the third country in WHO’s South-East Asia Region to do it, after Nepal and Myanmar.

Trachoma is a bacterial eye infection, the leading infectious cause of blindness worldwide, and in India in the 1970s it accounted for around 5% of all blindness. Eliminating it required no new science. It required mass azithromycin administration, surgery for advanced trichiasis, hygiene promotion, water and sanitation work, and a national trichiasis survey across 200 districts between 2021 and 2024. Decades of unglamorous logistics.

It joins a list: smallpox in 1977, polio in 2014, maternal and neonatal tetanus in 2015. Kala-azar is close, with cases down to 339 and a single death in 2024, and India waiting on the sustained-performance window WHO requires before certification.

TB remains the hard one. Incidence fell from 237 per 100,000 in 2015 to 195 in 2023, which is real progress against the largest TB burden in the world, and still leaves the largest TB burden in the world.

Scale is the other half of the breakthrough

None of the above reaches anyone without delivery infrastructure, and this is where India’s numbers stop being comparable to other countries.

Ayushman Bharat PM-JAY, launched in 2018, provides cover of ₹5 lakh per family per year for secondary and tertiary care, with over 434 million Ayushman cards issued and reported savings to families exceeding ₹1.25 lakh crore in 2024–25 alone. Primary care runs through more than 184,000 Ayushman Arogya Mandirs. The digital layer, the Ayushman Bharat Digital Mission, had issued over 863 million health IDs by February 2026.

The screening figures are the ones that show what that infrastructure can do when pointed at something. As of October 2025: over 401 million hypertension screenings, 398 million for diabetes, 338 million for oral cancer, 158 million for breast cancer. Medicines flow through nearly 18,000 Jan Aushadhi Kendras at 50 to 90% below market price, with around ₹30,000 crore saved by patients over the decade.

In February 2026 the country launched a national HPV vaccination programme, offering a single-dose quadrivalent vaccine free to 14-year-old girls, with roughly 11.5 million currently eligible. Cervical cancer is among the leading cancer killers of Indian women. This is the intervention that changes that number, and it will take twenty years to show up in mortality data.

And in the same month, the Health Ministry launched SAHI, the Strategy for Artificial Intelligence in Healthcare for India, making India the first country in the WHO South-East Asia Region with a national AI strategy for health.

What none of this has fixed

An article that stopped here would be a brochure. The gaps are as real as the achievements, and clinicians know them better than anyone.

Doctor density remains below WHO’s benchmark, unevenly distributed, and concentrated in cities. Medical education has expanded sharply — MBBS seats up around 130% and postgraduate seats up around 138% over roughly a decade — but a seat created today is a consultant in a district hospital sometime in the 2030s, if the distribution problem gets solved separately.

Out-of-pocket expenditure still drives Indian families into poverty despite PM-JAY, because coverage gaps, outpatient costs and diagnostics sit largely outside the scheme.

Data quality is the quiet constraint on everything digital. Having 863 million health IDs is not the same as having 863 million structured, complete, analysable records, and the difference is exactly what limits how useful AI can be in this system.

And the non-communicable disease wave is arriving faster than the infrastructure built for infectious disease can be repurposed. Screening hundreds of millions of people for hypertension and diabetes is only valuable if the follow-up capacity exists for everyone who screens positive.

Why it matters past India

The countries watching this most closely are not in the West.

A therapy at one-tenth the price, a scanner at a fraction of import cost, a biosimilar at a third — those are not primarily Indian achievements. They are proof for every health system that has been told advanced medicine is structurally unaffordable for its population. India’s pharmaceutical exports already carry a version of this argument to about 200 countries. Its cell and gene therapy work is starting to carry a more ambitious one.

The breakthrough was never going to be a single molecule. It was working out how to build the thing, prove it, price it and deliver it to a billion and a half people. That is the harder problem, and it is the one worth watching.

Sources

Figures are drawn from government and WHO sources as published and are current to early 2026. Verify before citing in clinical or regulatory material.